IT STARTS WITH
UNDERSTANDING SAFETY AND TOLERABILITY
SOLAR results were consistent with the overall profile of every-2-month VOCABRIA + REKAMBYS
*Represents the number of participants who received an injection.
†A single injection could result in more than one ISR. Grading was missed for one ISR event in the every‑2‑month VOCABRIA + REKAMBYS start with injection (SWI) group.
‡There were no Grade 4 or Grade 5 ISRs.
§Includes participants who discontinued due to ISR AEs, and an additional participant who withdrew from the study citing injection intolerability. This also includes one participant who was excluded from the primary analysis (mITT‑E) population.
AE=adverse event; BIC/FTC/TAF=bictegravir/emtricitabine/tenofovir alafenamide; IQR=interquartile range; ISR=injection site reaction; SmPC=summary of product characteristics; SWI=start with injection.
- Ramgopal MN, Castagna A, Cazanave C, et al. SOLAR 12-Month Results – Randomized Switch Trial of CAB + RPV LA vs. Oral BIC/FTC/TAF. Presented at Conference on Retroviruses and Opportunistic Infections (CROI): February 19–22, 2023. REF-182990.
- Data on file. Study 213500 Month 12 analysis for CAB+RPV Q2M incidence of drug-related ISR AEs Overall. January 2023. REF-183162. ViiV Healthcare group of companies.
- VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
- REKAMBYS Summary of Product Characteristics. Janssen.
REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under licence by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.